cbd

The Year Ahead for Leef Brands’ Growth Story

LEEF Brands heads into 2026 with something rare in cannabis: visible operational…

Wilson Augustine
January 8, 2026

Investor Opportunity: U.S. Government Focus on CBD as Medicine

The potential for federal cannabis rescheduling is rightly getting a lot of…

Wilson Augustine
December 23, 2025

A Close Look at Cardiol Therapeutics’ Phase 2 Results Shows the Path Forward

Not all clinical trial results are cut and dried. Sometimes the outcome…

Robin Lefferts
December 9, 2025

Investor Opportunity: Big Pharma Patent Cliff Spurring Surge in M&A Activity

Here’s the short version: Big pharma is staring down a real patent…

Robin Lefferts
November 18, 2025

Cardiol Therapeutics’ Financing Paves Way for Heart Failure Drug Development

Smaller pharmaceutical companies embark on an exciting journey as they seek to…

Robin Lefferts
October 29, 2025

Phase II Results Point the Way Forward for Cardiol Therapeutics

For smaller public company drug developers clinical trial results are major catalytic…

Robin Lefferts
September 16, 2025

Consumer Product Stocks

Scientific Breakthrough Greatly Improves Bioavailability and Speed of Action for Oil Soluble Active Ingredients, Including Antioxidants and Other Nutraceuticals

UltraShear™ Technology (UST™) is a revolutionary high-pressure nanoemulsification homogenization system developed by Pressure…

Robin Lefferts
August 14, 2025

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx™ in Acute Myocarditis

Toronto, Ontario–(Newsfile Corp. – August 6, 2025) – Cardiol Therapeutics Inc. (NASDAQ: CRDL)…

Ryan Allway
August 6, 2025

Former Eli Lilly CMO Joins Cardiol’s Board, Bolstering Drug Development, Clinical Trial, and Commercial Expertise

As smaller clinical stage pharmaceutical companies advance drug candidates from the lab…

Robin Lefferts
May 29, 2025

These Healthcare Stocks Significantly Outperformed the Industry in 2024

While the stock market broadly experienced significant gains in 2024, a few…

Robin Lefferts
January 27, 2025

The Year Ahead for Leef Brands’ Growth Story

Investor Opportunity: U.S. Government Focus on CBD as Medicine

A Close Look at Cardiol Therapeutics’ Phase 2 Results Shows the Path Forward

Investor Opportunity: Big Pharma Patent Cliff Spurring Surge in M&A Activity

Cardiol Therapeutics’ Financing Paves Way for Heart Failure Drug Development

Phase II Results Point the Way Forward for Cardiol Therapeutics

Scientific Breakthrough Greatly Improves Bioavailability and Speed of Action for Oil Soluble Active Ingredients, Including Antioxidants and Other Nutraceuticals

Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx™ in Acute Myocarditis

Former Eli Lilly CMO Joins Cardiol’s Board, Bolstering Drug Development, Clinical Trial, and Commercial Expertise

These Healthcare Stocks Significantly Outperformed the Industry in 2024

Don Kreski

Robin Lefferts

Ryan Allway

Wilson Augustine

Are We Underestimating Aduro’s Revenue Potential?

The Year Ahead for Leef Brands’ Growth Story

Investment Opportunity: 2026 Is a Pivotal Year for Plastic Recycling Upstart

Investor Opportunity: U.S. Government Focus on CBD as Medicine

Sign Up for Our Newsletter